Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Dow Jones06-08

By Adriano Marchese

Cullinan Therapeutics shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus and rheumatoid arthritis patients.

Shares traded 9.6% higher ahead of the morning bell at $14.81.

The clinical-stage biopharmaceutical said a single dose of its CD19xCD3 T-cell engager, called CLN-978, led to clinical improvements and even remissions in patients with hard-to-treat lupus and rheumatoid arthritis.

A CD19xCD3 T-cell engager is a type of next-generation immune therapy designed to force T-cells to kill B-cells, the kind that sustain autoimmune diseases like lupus and rheumatoid arthritis.

Cullinan said that the early results showed deep, dose-dependent B-cell depletion and a safety profile that it said supports further clinical development.

"We are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients," Chief Medical Officer Jeffrey Jones said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 08, 2026 06:38 ET (10:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641548549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641548549","market":"sh","top_or_hot":-1,"title":"Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus and rheumatoid arthritis patients. \n</p>\n<p>\n  Shares traded 9.6% higher ahead of the morning bell at $14.81. \n</p>\n<p>\n  The clinical-stage biopharmaceutical said a single dose of its CD19xCD3 T-cell engager, called  CLN-978, led to clinical improvements and even remissions in patients with hard-to-treat lupus and rheumatoid arthritis. \n</p>\n<p>\n  A CD19xCD3 T-cell engager is a type of next-generation immune therapy designed to force T-cells to kill B-cells, the kind that sustain autoimmune diseases like lupus and rheumatoid arthritis. \n</p>\n<p>\n  Cullinan said that the early results showed deep, dose-dependent B-cell depletion and a safety profile that it said supports further clinical development. \n</p>\n<p>\n  \"We are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients,\" Chief Medical Officer Jeffrey Jones said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 06:38 ET (10:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-08 18:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus and rheumatoid arthritis patients. \n</p>\n<p>\n  Shares traded 9.6% higher ahead of the morning bell at $14.81. \n</p>\n<p>\n  The clinical-stage biopharmaceutical said a single dose of its CD19xCD3 T-cell engager, called  CLN-978, led to clinical improvements and even remissions in patients with hard-to-treat lupus and rheumatoid arthritis. \n</p>\n<p>\n  A CD19xCD3 T-cell engager is a type of next-generation immune therapy designed to force T-cells to kill B-cells, the kind that sustain autoimmune diseases like lupus and rheumatoid arthritis. \n</p>\n<p>\n  Cullinan said that the early results showed deep, dose-dependent B-cell depletion and a safety profile that it said supports further clinical development. \n</p>\n<p>\n  \"We are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients,\" Chief Medical Officer Jeffrey Jones said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 06:38 ET (10:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2641548549","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641548549","pubTimestamp":1780915080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cullinan Therapeutics shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus and rheumatoid arthritis patients.Shares traded 9.6% higher ahead of the morning bell at $14.81.The clinical-stage biopharmaceutical said a single dose of its CD19xCD3 T-cell engager, called  CLN-978, led to clinical improvements and even remissions in patients with hard-to-treat lupus and rheumatoid arthritis.A CD19xCD3 T-cell engager is a type of next-generation immune therapy designed to force T-cells to kill B-cells, the kind that sustain autoimmune diseases like lupus and rheumatoid arthritis.Cullinan said that the early results showed deep, dose-dependent B-cell depletion and a safety profile that it said supports further clinical development.\"We are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CGEM":"Cullinan Therapeutics"},"translate_title":"Cullinan Therapeutics股价因自身免疫药物早期试验数据积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\nCullinan Therapeutics shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus and rheumatoid arthritis patients. \n\n\n  Shares traded 9.6% higher ahead of the morning bell at $14.81. \n\n\n  The clinical-stage biopharmaceutical said a single dose of its CD19xCD3 T-cell engager, called  CLN-978, led to clinical improvements and even remissions in patients with hard-to-treat lupus and rheumatoid arthritis. \n\n\n  A CD19xCD3 T-cell engager is a type of next-generation immune therapy designed to force T-cells to kill B-cells, the kind that sustain autoimmune diseases like lupus and rheumatoid arthritis. \n\n\n  Cullinan said that the early results showed deep, dose-dependent B-cell depletion and a safety profile that it said supports further clinical development. \n\n\n  \"We are focused on advancing CLN-978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients,\" Chief Medical Officer Jeffrey Jones said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:38 ET (10:38 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641548549","isCrawlerRequest":true}